purpose : to evaluate indications, risk factors and outcome of repeat penetrating keratoplasty (pkp) at a tertiary referral eye care center methods : in this retrospective study, medical chart of patients who underwent repeat pkp at labbafinejad medical center between january 2004 and december 2009 were reviewed. results : a total of 1,859 corneal transplantations were performed on 1,624 eyes d...

Background: Autoimmune bullous diseases (AIBDs) represent a group of acquired heterogenous organ-specific disorders in which pathogenic autoantibodies, commonly of IgG and/or IgA classes, target adhesion molecules of the skin and mucous membranes. These disorders are caused by the interaction between autoantibodies and structures essential for the integrity of the skin, either on keratinocytes ...

Lichen planus pemphigoides (LPP) is a rare autoimmune blistering disease that is characterized by the development of vesico-bullous skin lesions in patients with lichen planus. The histopathology of LPP reveals a sub_epidermal blister with linear deposition of IgG and /or C3 along the dermal_epidermal junction (DEJ) upon direct immunofluorescence (DIF). We hereunder describe a case of lichen pl...

Toxic epidermal necrolysis is a rare but clinically well-described dermatological pathology. However, clinical pictures of this disorder in text books do not reflect its dynamic evolution. Usually, the desquamative post-bullous stage is represented, neglecting the initial bullous stage as well as the skin healing. With one clinical case, we provide a day-after-day illustration of the evolution ...

BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been reported with ustekinumab. We report a...

Bullous pemphigoid is a rare complication of immune checkpoint inhibitor treatment. We report case pembrolizumab-induced bullous in patient with malignant melanoma and concomitant cutaneous squamous cell carcinoma that regressed. A 77-year-old woman metastatic 3-year history growing skin nodule on her left calf was treated pembrolizumab. Histopathological examination the established diagnosis c...

We describe an unusual case of severe pulmonary bullous disease developing during treatment of marginal zone B-Cell lymphoma (MALT) involving the pulmonary parenchyma. The patient originally presented with pneumonia-like symptoms along with hemoptysis and was diagnosed with MALT lymphoma after a video-assisted thoracic surgical (VATS) lung biopsy. Computed tomography (CT) of the chest at diagno...